An emerging family of cell surface inhibitory receptors is characterized by the presence of intracytoplasmic immunoreceptor tyrosine-based inhibition motifs (ITIM). These ITIM-bearing inhibitory receptors, which are typically paired with activating isoforms, associate with Src homology domain 2-containing phosphatases following ITIM tyrosine phosphorylation. Two categories of phosphatases are recruited by the ITIM-bearing receptors: the protein-tyrosine phosphatases, SHP-1 and SHP-2, and the polyphosphate inositol 5-phosphatase, SHIP. The dynamic equilibrium of B cell activation is partially controlled by two well known ITIM-bearing receptors, CD22 and Fc␥RIIB, a low affinity receptor for IgG. We describe here that a murine ITIMbearing molecule, PIR-B, can also negatively regulate B cell activation. Tyrosine-phosphorylated ITIMs allow PIR-B to associate with SHP-1 but not with SHIP. Engagement of PIR-B thereby initiates a SHP-1-dependent inhibitory pathway that may play an important role in regulating B lymphocyte activation.
The regulation of cell activation involves a dynamic equilibrium between activating and inhibitory signals. Intracytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM)-bearing receptors that are defined by one or more consensus ITIM (I͞L͞V͞S)XYXX(L͞V) in their intracytoplasmic domain mediate an inhibitory function through recruitment of Src homology domain 2 (SH2)-containing intracytoplasmic phosphatases (1, 2) . The phosphatases recruited by the tyrosine-phosphorylated form of ITIMs belong to one of two classes: the SHP-1 and SHP-2 protein-tyrosine phosphatases or the polyphosphate inositol 5-phosphatase SHIP (3) . ITIMbearing receptors belong to a large family of molecules with more than 30 distinct members (1, 4) . Except for the IgG receptor, Fc␥RIIB, and the type C lectins, human NKG2A͞B and mouse Ly-49s, all ITIM-bearing molecules are encoded by Ig superfamily genes present on human chromosome 19q13 and its syntenic region on mouse chromosome 7. The genes for the Ig-like ITIM-bearing molecules share a conserved organization in which ITIMs are encoded by a single exon preceded by a type 0 intron (5) . ITIM-bearing receptors are characteristically paired with activating receptors, which share highly similar extracellular domains but harbor a shorter cytoplasmic domain devoid of ITIM. The activating receptor isoforms are not alternative spliced products of the ITIM-bearing receptor genes but are instead encoded by separate genes. The activating receptor isoforms have a charged amino acid residue in their transmembrane domain, which may allow their association with signal-transducing proteins, as demonstrated recently for killer cell-activating receptors (6, 7) .
The paired Ig-like receptors (PIR) recently identified on murine B cells and myeloid-lineage cells include PIR-A molecules, with a short cytoplasmic domain, and PIR-B molecules, which bear a long cytoplasmic domain (178 amino acids) that contains three potential ITIMs centered on tyrosine residues Tyr-713 (SLYASV), Tyr-794 (VTYAQL), and Tyr-824 (SVYATL) (8) . The six Ig-like domains in the extracellular region of mouse PIR-B share sequence homology with the two to four Ig-like domain-containing molecules, ILT-2͞LIR-1, LIR-2, LIR-3, ILT-3͞LIR-5, and LIR-8 (9) (10) (11) , which may represent their human homologues. In this report, we characterize the inhibitory features of the PIR-B molecules.
MATERIALS AND METHODS
Antibodies. Rat monoclonal antibodies (mAbs), 10.4 and 6C1, specific for PIR-A and PIR-B molecules (H.K., C.C.C., and M.D.C., unpublished work) were digested with pepsin before passage over a protein-G column to separate the F(abЈ) 2 fragments, which were then biotinylated. Other mAbs included a mouse anti-2,4,6-trinitrophenyl IgE mAb (2682-1), a rat anti-2,4,6-trinitrophenyl IgE mAb (LO-DNP 30) (12), a mouse anti-rat FcRI␣ mAb (BC4, ␥1; the gift of R. Siraganian, National Institutes of Health, Bethesda, MD), a rat anti-mouse Fc␥RII͞III mAb (2.4G2; ␥2b), and a murine anti-phosphotyrosine mAb (4G10; Upstate Biotechnology, Lake Placid, NY). Polyclonal antibodies included F(abЈ) 2 fragments of goat anti-mouse Ig antibody (GAM), F(abЈ) 2 fragments of donkey anti-mouse Ig antibodies lacking crossreactivity to rat Ig (DAM), F(abЈ) 2 fragments of donkey anti-rat Ig antibodies lacking cross-reactivity to mouse Ig (DAR) (Immunotech, Luminy, France), and biotin-labeled F(abЈ) 2 fragments of goat anti-mouse -chain antibodies (Southern Biotechnology Associates).
Peptides. Mouse PIR-B and Fc␥RIIBI peptides containing an N-terminal-biotin were synthesized in phosphorylated and nonphosphorylated forms (Neosystem, Strasbourg, France): CD3, KEPPPVPNPDYEPIRK; Fc␥RIIBI, KTEAENTI-TYSLLK; PIR-B Tyr-713, AAATQEESLYASVED; PIR-B Tyr-742, PEEDPQGET YAQVKP; PIR-B Tyr-770, MSR EQLNTEYEQAEE; PIR-B Tyr-794, ESGESQD-VTYAQL; PIR-B Tyr-824, GEAPEEPSVYATLAA.
cDNA Constructs. The cDNA constructs were generated from a pNT-Neo plasmid including a chimeric cDNA encoding the extracellular, transmembrane, and the first six amino acids (KKKQVP) of the intracellular region of murine Fc␥RIIB1 fused with the intracellular region of mouse PIR-B (Fc␥RIIB͞ PIR-B) obtained by PCR amplification of the pBluescript-7M5 plasmid (8) . The primers generated 5Ј KpnI and 3Ј SacI sites, allowing in frame ligation with the Fc␥RIIB1 sequence in pNT-Neo plasmid. Point mutation constructs were generated by PCR-directed mutagenesis of the Fc␥RIIB͞PIR-B construct. Each point mutation involved a tyrosine replacement by phenylalanine. The tyrosine at position 794 in PIR-B was mutated in the Fc␥RIIB͞PIR-BY794F mutant, the tyrosine at position 824 in the Fc␥RIIB͞PIR-BY824F mutant, and both tyrosines in the Fc␥RIIB͞PIR-BY794F,Y824F mutant (Fig.  2 A) . Fidelity of the constructs was verified by sequencing (Genome Express, Grenoble, France).
Cell Transfection. RBL-2H3 cells cultured in DMEM supplemented with 10% fetal calf serum, 100 international units͞ml penicillin, and 100 g͞ml streptomycin (complete medium) were transfected by electroporation (12) . Stable transfectants were established by culture in the presence of G418 (1 mg͞ml), and representative clones were selected for further investigation.
Calcium Mobilization Analysis. Splenocytes from BALB͞c mice were incubated for 30 min at 37°C in HBSS (5 ϫ 10 6 cells per ml) containing 5% fetal calf serum and 1 g͞ml Indo-1͞AM (Calbiochem). Cells held at room temperature for 5 min were resuspended either in HBSS containing 5% fetal calf serum or calcium-free HBSS containing 2 mM EGTA (10 6 cells per ml). The 395͞520 nm fluorescence ratio for viable cells preloaded with Indo-1͞AM dye was determined with a FACStar Plus flow cytometer equipped with an argon ion laser operated in UV mode (Becton Dickinson). After establishing the baseline, 10 g of biotin-labeled F(abЈ) 2 goat anti-mouse and͞or F(abЈ) 2 anti-PIR mAbs were added to the dye-loaded cells, followed by the addition of Neutralite avidin 10 g (SBA) as a cross-linker. Data represent Ϸ80,000 events collected over 5-8 min.
Serotonin Release. RBL-2H3 cell transfectants were examined for serotonin release as described (12) . Briefly, cells were incubated at 37°C for 1 h with 2 mCi͞ml [ 3 H]serotonin (Amersham), washed, incubated for another hour at 37°C, washed again, and distributed in 96-well microculture plates at 2 ϫ 10 5 cells͞well. Cells were then incubated for 1 h with IgE and the 2.4G2 anti-Fc␥R antibody in a final volume of 50 l, washed, and then challenged for 30 min at 37°C with 25 l of prewarmed GAM, DAM, or DAR F(abЈ) 2 fragments. Reactions were stopped by adding 50 l of ice-cold medium and by placing plates on ice. [ 3 H]Serotonin content in the supernatants was assayed as described (12) .
Fusion Protein Analysis by Surface Plasmon Resonance. Surface plasmon resonance measurements were made with a BIAcore apparatus (BIAcore) using GST-SHP 1.SH2(NC), GST-SHP 2.SH2(NC), and GST-SHIP.SH2 fusion proteins generated from murine phosphatase cDNAs and purified from DH5␣ lysates as previously described (13) . Before assay, fusion proteins were dialyzed in pH 7.4 HBS buffer (10 mM Hepes͞ 150 mM NaCl͞3.4 mM EDTA). Protein purity was assessed by SDS-12.5% PAGE and Coomassie Blue staining. HBS buffer supplemented with 0.05% surfactant P20 was used as the injection medium in BIAcore experiments employing biotinylated peptides immobilized on streptavidin microchips (13) . (ICN) and incubated overnight at 37°C as described (14) . Briefly, after lysis, samples were precleared with control peptide (nonphosphorylated CD3 ITAM peptide) immobilized on streptavidin-agarose beads (Sigma) prior to analysis in the cell lysate adsorption assay. Indicated biotinylated peptides (5 g) were coupled to 50-l streptavidinagarose slurry beads for 1 hr at 4°C prior to bead saturation with D-biotin (1 mg͞ml) for 1 h at 4°C. Cell lysates were incubated with peptide-coated beads for 2 h at 4°C, and after three washes in lysis buffer, samples were fractionated on SDS-8% PAGE under reducing conditions.
Immunoprecipitation and Immunobloting. Fc␥RIIB͞PIR-B.H transfectants of RBL-2H3 cells were stimulated with mouse IgE (1͞10 final dilution of hybridoma supernatant) in complete medium in the presence or absence of F(abЈ) 2 fragments of the 2.4G2 mAb (3 g͞ml) before washing and stimulation for 2 min at 37°C with 20 g͞ml F(abЈ) 2 fragments of GAM. Immunoprecipitation and immunoblotting of proteins in the cell lysates were performed as described in ref. 15 . Fig. 1) , co-aggregation of Fc␥RIIB͞PIR-B with the FcRI complex led to an inhibition of IgE-induced serotonin release for both RBL Fc␥RIIB͞PIR-B.H and RBL Fc␥RIIB͞PIR-B.L cells, whereas no effect was observed for mock-transfected RBL cells (Fig. 3) . The inhibitory function mediated by the PIR-B cytoplasmic domain was dependent upon the dosage of IgE used to induce FcRI cross-linkage (Fig. 3A) . The inhibitory function of the PIR-B fusion protein was profound at suboptimal concentrations of IgE, being 56-77% between 10 Ϫ3 and 10
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IgE dilutions, and was reduced at optimal and supraoptimal IgE concentrations, being 21-38% between 10 Ϫ2 and 3 ϫ 10
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IgE dilutions. Using mouse and rat IgE, both of which bind to the FcRI complex on RBL-2H3 cells, we investigated whether co-aggregation of FcRI and Fc␥RIIB͞ PIR-B molecules is required for the inhibition. As shown in motif (1, 2) . ITIMs may associate with either the protein-tyrosine phosphatases, SHP-1 and SHP-2, or the polyphosphate inositol 5-phosphatase, SHIP. When synthetic phosphopeptides corresponding to 15-amino acid stretches (including each of the PIR-B intracytoplasmic tyrosine residues) were used to adsorb lysates prepared from 35 S metabolically labeled B cells (Fig. 4A) , two prominent protein bands of 64 and 68 kDa were found to bind selectively to the synthetic peptides that included the phosphorylated form of Tyr-794 and Tyr-824. No consistent association was detected with nonphosphorylated peptides or phosphorylated forms of the Tyr-742 and Tyr-770 peptides, and only minimal binding of 68 and 85 kDa proteins were detected for the phosphorylated peptide corresponding to Tyr-713. The 64-and 68-kDa proteins comigrated with SHP-1 and SHP-2 bands previously shown to associate with the phosphorylated Fc␥RIIB1 ITIM peptide (16, 17) . No protein association was observed for the nonphosphorylated forms of Fc␥RIIB (Fig. 4A) or recombinant PIR-B (data not shown). Importantly, none of the phosphorylated PIR-B peptides could be shown to associate with SHIP (Ϸ145 kDa), a finding that contrasts with the binding of SHIP to the phosphorylated form of Fc␥RIIB (Fig. 4A) .
Surface plasmon resonance was used to examine the direct binding of the PIR-B phosphopeptides to the soluble recombinant SH2 domains of SHP-1, SHP-2, and SHIP. These studies employed the phosphorylated Fc␥RIIB ITIM peptide as a positive control, as it can associate with all three phosphatases in vitro. Phosphopeptides corresponding to the PIR-B Tyr-794 and Tyr-824 motifs both bound to the tandem SH2 domains of SHP-1 and SHP-2, and a weaker but detectable association was observed between the SHIP SH2 domain and the Tyr-824 phosphopeptide. Comparable binding of the phosphatase SH2 domains was not detected with phosphopeptides corresponding to the PIR-B Tyr-742 or Tyr-770 motifs; only minimal binding with SHP-2 was observed for the PIR-B Tyr-713 phosphopeptide (data not shown). These results indicate that the phosphorylated forms of PIR-B Tyr-794 and (Fig. 4C, Upper, lane 4) , whereas no association of the PIR-B cytoplasmic domain with SHP-2 or SHIP could be detected (data not shown). Weak constitutive association of the PIR-B cytoplasmic domain with SHP-1 was also observed. Tyrosine phosphorylation of the PIR-B chimera was detected upon Fc␥RIIB͞PIR-B and FcRI co-engagement (Fig. 4C,  Lower, lane 4) , as well as following Fc␥RIIB͞PIR-B stimulation (Fig. 4C, Lower, lane 2) . We did not detect any association of FcRI with SHP-1, SHP-2, or SHIP in this experimental model (Fig. 4C, Upper, lane 3 , and data not shown) in contrast to previous reports (19, 20) .
Mutations of Tyr-794 and Tyr-824 Impair the PIR-B Inhibitory Function. Because the binding assays clearly implicated the two ITIMs centered on Tyr-794 and Tyr-824 in the inhibitory function of PIR-B, Y794F and Y824F point mutants of the Fc␥RIIB͞PIR-B chimeric molecule were generated. Stable RBL-2H3 cell transfectants were obtained, which expressed Fc␥RIIB͞PIR-B, Fc␥RIIB͞PIR-B.Y794F, and Fc␥RIIB͞PIR-B.Y824F at similar cell surface densities. However, RBL-2H3 cell transfectants expressing reduced levels of the chimeric molecule were obtained when both Tyr-794 and Tyr-824 were mutated. No significant alteration of PIR-B inhibitory function was detected in the serotonin release assay when the endogenous FcRI receptor was co-aggregated with the Y794F or Y824F single mutants (Fig. 3C) , suggesting that the PIR-B ITIMs may be redundant. Simultaneous mutation of both Tyr-794 and Tyr-824 led to significant impairment of the PIR-B inhibitory function (Fig. 3C) , although the Fc␥RIIB͞PIR-B.Y794F,Y824F double mutant molecule was still capable of partial inhibition of the FcRI-induced activation.
DISCUSSION
The results presented in this report establish an inhibitory function for PIR-B on murine B cells and show that its tyrosine-phosphorylated ITIMs can recruit the proteintyrosine phosphatase SHP-1. These observations raise several issues relative to the function and mechanisms of action of the PIR-B molecules.
The , indicating that PIR-B aborts the initial release of Ca 2ϩ from the intracellular stores. These observations, which parallel those following KIR and ILT-2 engagement (12, 22) and contrast with those following engagement of Fc␥RIIB, a SHIP-associating molecule (26) , support the idea that SHP-1 substrates are upstream signaling molecules in proteintyrosine kinase-dependent activating pathways. The KIRs have similarly been shown to recruit SHP-1, which in turn dephosphorylates tyrosine-phosphorylated substrates including pp36-38 and ZAP-70 (27, 28) . It is likely therefore that the co-engagement of PIR-B and BCR leads to the dephosphorylation of tyrosine-phosphorylated proteins, such as Syk, belonging to the BCR-dependent signaling cascade.
ITIM-bearing receptors on B cells thus include Fc␥RIIB, CD22, and PIR-B. The SHIP-independent mechanism of action for PIR-B constitutes an alternative inhibitory pathway to that initiated by Fc␥RIIB and could contribute to significant in vivo differences, as exemplified by the differential regulation of Ca 2ϩ mobilization. The SHP-1-deficient motheaten mouse exhibits severe B cell immunodeficiency and auto-antibody production. In addition, decrease of SHP-1 expression has been demonstrated for germinal center B cells, which have a low threshold for cellular activation (29) . Consistent with these observations, SHP-1 is involved in a ''censoring'' mechanism that determines the threshold of B cell activation through the BCR, thereby affecting the negative selection of B cells (30) . The control of BCR signals by SHP-1 might be mediated via ITIM-bearing receptors such as PIR-B and CD22. CD22 may serve as a continuous negative regulator of BCR-induced B cell activation (31) and regulates calcium entry into B cells by a mechanism downstream from or independent of calcium release from intracellular stores (32) . PIR-B thus provides an alternative inhibitory pathway for B cells, one that is complementary to those exerted by Fc␥RIIB and CD22.
